Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Pieter L. Jager"'
Autor:
Nanno Schreuder, Iris de Romijn, Pieter L. Jager, Jos G. W. Kosterink, Eugène P. van Puijenbroek
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-23 (2021)
Abstract Background Patients with chronic kidney disease (CKD) may need to have their radiopharmaceutical dosage adjusted to prevent adverse effects and poor outcomes, but there are few recommendations on radiopharmaceutical dosing for this group of
Externí odkaz:
https://doaj.org/article/d932373e23494cf78b1bb93a6cb5ec73
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-8 (2019)
Abstract Background A high SUV-reproducibility is crucial when different PET scanners are in use. We evaluated the SUV variability in whole-body FDG-PET scans of patients with suspected or proven cancer using an EARL-accredited conventional and digit
Externí odkaz:
https://doaj.org/article/3356ba6cb46e430f98d1c4231c8193e9
Autor:
Sabine S. Koenders, Jorn A. van Dalen, Pieter L. Jager, Mohamed Mouden, Cornelis H. Slump, Joris D. van Dijk
Publikováno v:
International journal of cardiovascular imaging, 38, 2743-2751. Springer
Purpose Visual assessment of Rubidium (Rb-82) PET myocardial perfusion images is usually combined with global myocardial flow reserve (MFR) measurements. However, small regional blood flow deficits may go unnoticed. Our aim was to compare the diagnos
Autor:
Daniëlle Koopman, Jorn A. van Dalen, Hester Arkies, Ad H. J. Oostdijk, Anne Brecht Francken, Jos Bart, Cornelis H. Slump, Siert Knollema, Pieter L. Jager
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-10 (2018)
Abstract Background We evaluated the diagnostic implications of a small-voxel reconstruction for lymph node characterization in breast cancer patients, using state-of-the-art FDG-PET/CT. We included 69 FDG-PET/CT scans from breast cancer patients. PE
Externí odkaz:
https://doaj.org/article/28673eac9eba457cb76ab3e918a12a13
Autor:
Tonke L. de Jong, Daniëlle Koopman, Jorn A. van Dalen, Aline Tegelaar, Joris D. van Dijk, Henk Stevens, Pieter L. Jager
Publikováno v:
Annals of Nuclear Medicine. 36:756-764
Autor:
Jos G. W. Kosterink, Iris de Romijn, Eugène van Puijenbroek, Pieter L. Jager, Nanno Schreuder
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-23 (2021)
EJNMMI Radiopharmacy and Chemistry
EJNMMI Radiopharmacy and Chemistry
Background Patients with chronic kidney disease (CKD) may need to have their radiopharmaceutical dosage adjusted to prevent adverse effects and poor outcomes, but there are few recommendations on radiopharmaceutical dosing for this group of patients.
Autor:
Tonke L. de Jong, Daniëlle Koopman, Corné A.J. van der Worp, Henk Stevens, Floris A. Vuijk, Alexander L. Vahrmeijer, J. Sven D. Mieog, Jan-Willem B. de Groot, Maarten A.C. Meijssen, Vincent B. Nieuwenhuijs, de Geus-Oei Lioe-Fee, Pieter L. Jager, Gijs A. Patijn
Publikováno v:
Surgical Oncology. 47:101909
Autor:
Siert Knollema, Daniëlle Koopman, Jorn A. van Dalen, Henk Stevens, Pieter L. Jager, Cornelis H. Slump
Publikováno v:
The Journal of nuclear medicine, 61(10), 1448-1454. Society of Nuclear Medicine Inc.
Recently introduced PET systems using silicon photomultipliers with digital readout (dPET) have an improved timing and spatial resolution, aiming at a better image quality than conventional PET (cPET) systems. We prospectively evaluated the performan
Autor:
Eugène van Puijenbroek, Pieter L. Jager, Brian N. Vendel, Hedwig Klarenbeek, Jos G. W. Kosterink, Nanno Schreuder
Publikováno v:
ANNALS OF NUCLEAR MEDICINE, 34(11), 833-839. SPRINGER
Annals of Nuclear Medicine
Annals of Nuclear Medicine
Objective In this retrospective, single-center observational study, we investigated whether discontinuing metformin for at least 48 h prevents metformin-induced [18F]fluorodeoxyglucose (FDG) uptake in all segments of the colon. Methods Patients with
Autor:
Pieter L. Jager, Nanno Schreuder, Jos G. W. Kosterink, Sieta T. de Vries, Eugène van Puijenbroek, Quincy de Hoog
Publikováno v:
Drug Safety
Drug Safety, 43(4), 319-328. ADIS INT LTD
Drug Safety, 43(4), 319-328. ADIS INT LTD
Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient’s perspective could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using radiopharmaceut